Stocks Under $10: Medical, Biomed/Genetics

Richard Suttmeier |

Stocks Under $10: Medical, Biomed/GeneticsAt we show that the Medical sector is 5.5% overvalued. The Medical-Biomed/genetics industry is 13.5% overvalued. All eight of the stocks in today’s table have complete ValuEngine data and most have enough price data to have enough value levels, risky levels and pivots.

BioDelivery Sciences Intl, Inc. (BDSI) – has been below $8.50 for at least five years.
Cambrex Corporation. (CBM) – moved above $10 on August 2, 2012 to a high of $14.33 on October 17 then broke below $10 again on November 6.
IFinix Corp. (INIX) – moved above $10 on January 9, 2012 to a high of $15.25 on January 19 then broke below $0 again on August 1.
Isis Pharmaceuticals, Inc. (ISIS) – moved above $10 on May 30, 2012 to a high of $15.61 on September 21 then broke below $10 again on October 17.
Neogenomics Inc. (NGNM) – has been below $3.50 for at least five years but has moved above $2.00 mid-year 2012.
PDL BioPharma, Inc. (PDLI) – has been below $10 since the week of May 16, 2008.
Repligen Corp. (RGEN) – has been between $2.50 and $7.50 for at least five years.
RTI Biologics, Inc. (RTIX) – has been below $10 since the week of October 3, 2008.

Stocks Under $10: Medical, Biomed/Genetics(Click to Enlarge)

Reading the Table

OV / UN Valued – The stocks with a red number are undervalued by this percentage. Those with a black number are overvalued by that percentage according to ValuEngine. The most overvalued stock in this table is NGNM by 70.8%. The most undervalued stock is IDIX by 31.0%.

VE Rating – A “1-Engine” rating is a Strong Sell, a “2-Engine” rating is a Sell, a “3-Engine” rating is a Hold, a “4-Engine” rating is a Buy and a “5-Engine” rating is a Strong Buy. We have four buy rated stocks and four Hold rated stocks.

Last 12-Month Return (%) – Stocks with a Red number declined by that percentage over the last twelve months. Stocks with a Black number increased by that percentage. The best performer over the past twelve months is BDSI with a gain of 324.5%. The biggest loser was IDIX with a loss of 33.6%.

Forecast 1-Year Return – Stocks with a Red number are projected to decline by that percentage over the next twelve months. Stocks with a Black number in the Table are projected to move higher by that percentage over the next twelve months. The biggest potential gainer is PDLI with a projected gain of 10.1%. The potential biggest loser is expected to be NGNM with a projected decline of 4.0%.

P/E Ratios – PDLI has a P/E ratio of just 5.5 while NGNM has an extremely elevated P/E of 284.0.

Value Level: is the price at which to enter a GTC Limit Order to buy on weakness. The letters mean; W-Weekly, M-Monthly, Q-Quarterly, S-Semiannual and A- Annual.

Pivot: A level between a value level and risky level that should be a magnet during the time frame noted.

Risky Level: is the price at which to enter a GTC Limit Order to sell on strength.

Where to Buy and Where to Sell

A “Value Level” is a price at which buyers should add to positions on market price weakness. A “Risky Level” is a price at which sellers should reduce holdings on market price gains. A "Pivot" is a support or resistance (Value Level or Risky Level) that was violated in its time horizon, acting as a magnet during the remainder of that time horizon.  These levels are calculated in weekly (W), monthly (M), quarterly (Q), semiannual (S) and annual (A) time horizons, based on the past nine closes in each time horizon. My theory is that the closes over a nine-year period are the summation of all bullish and bearish events for that market or specific stock. These levels are the most important element of my Buy and Trade Strategy.

Buy and Trade Guidelines

Investors should consider entering good until cancelled (GTC) orders to buy weakness to a value level, or to sell strength to a risky level.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to:


Symbol Name Price Change % Volume
BGCA BGC Partners Inc. 8.125% Senior Notes due 2042 26.13 0.15 0.57 352 Trade
RGEN Repligen Corporation 37.92 0.81 2.18 367,742 Trade
CBM Cambrex Corporation 52.55 0.00 0.00 266,573 Trade
ISIS Isis Pharmaceuticals Inc. n/a n/a n/a 0 Trade
BDSI BioDelivery Sciences International Inc. 2.95 0.15 5.36 479,657 Trade
PDLI PDL BioPharma Inc. 3.50 0.01 0.29 1,087,370 Trade
RTIX RTI Surgical Inc. 4.65 -0.10 -2.11 235,590 Trade


Emerging Growth

GTX Corp

GTX Corp, along with its subsidiaries, is engaged in design, development, manufacturing, distribution and sales of products and services in the GPS and BLE wearable technology personal location and wandering…

Private Markets

iPRO Network, LLC

We provide the platform, tools, and resources to empower individuals and professionals to market desirable goods and services to the public, taking the place of traditional methods of commerce.

Quants Inc

Quants, Inc, a California Corporation, develops, markets and operates financial technology platforms and alternative investment products offering sophisticated risk management since 2010. The Company has primarily sharpened its focus with…